Isolation of equine bone marrow-derived mesenchymal stem cells: A comparison between three protocols

Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, Québec, Canada.
Equine Veterinary Journal (Impact Factor: 2.37). 09/2010; 42(6):519-27. DOI: 10.1111/j.2042-3306.2010.00098.x
Source: PubMed


REASON FOR PERFORMING THE STUDY: There is a need to assess and standardise equine bone marrow (BM) mesenchymal stem cell (MSC) isolation protocols in order to permit valid comparisons between therapeutic trials at different sites.
To compare 3 protocols of equine BM MSC isolation: adherence to a plastic culture dish (Classic) and 2 gradient density separation protocols (Percoll and Ficoll).
BM aspirates were harvested from the sternum of 6 mares and MSCs isolated by all 3 protocols. The cell viability after isolation, MSC yield, number of MSCs attained after 14 days of culture and the functional characteristics (self-renewal (CFU) and multilineage differentiation capacity) were determined for all 3 protocols.
The mean +/- s.d. MSC yield from the Percoll protocol was significantly higher (6.8 +/- 3.8%) than the Classic protocol (1.3 +/- 0.7%). The numbers of MSCs recovered after 14 days culture per 10 ml BM sample were 24.0 +/- 12.1, 14.6 +/- 9.5 and 4.1 +/- 2.5 x 10(6) for the Percoll, Ficoll and Classic protocols, respectively, significantly higher for the Percoll compared with the Classic protocol. Importantly, no significant difference in cell viability or in osteogenic or chondrogenic differentiation was identified between the protocols. At Passage 0, cells retrieved with the Ficoll protocol had lower self-renewal capacity when compared with the Classic protocol but there was no significant difference between protocols at Passage 1. There were no significant differences between the 3 protocols for the global frequencies of CFUs at Passage 0 or 1.
These data suggest that the Percoll gradient density separation protocol was the best in terms of MSC yield and self-renewal potential of the MSCs retrieved and that MSCs retrieved with the Ficoll protocol had the lowest self-renewal but only at passage 0. Then, the 3 protocols were equivalent. However, the Percoll protocol should be considered for equine MSC isolation to minimise culture time.

Download full-text


Available from: Celine Bourzac, Sep 17, 2015
  • Source
    • "MSC are usually expanded in growth medium containing 10% foetal bovine serum (FBS) to provide essential proteins for cellular adhesion and growth. The most frequently used are DMEM (Kasashimae et al., 2011, Bourzac et al., 2010) and α-MEM (Arnhold et al., 2007). Technical studies used different medium for MSC culture (Peptanariu et al.2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) have been derived from multiple sources in the horse such as bone marrow, adipose tissue and umbilical cord blood. Bone marrow derived mesenchymal stem cells (BM-MSCs) can be used to repair articular cartilage defects. The aim of this study was to develop and optimize protocol for collection, isolation, culture. Specifically, these studies will compare site of stem cell collection and isolation technique of equine bone marrow derived mesenchymal stem cells. We collected bone marrow from 2 horses. Each horse was collected bone marrow at sternum and ileum. After percoll centrifugation, mononuclear cells (MNC) were collected and either perform RBC lysis or non-lysis. We used MSC1 and MSC3 to study expanding media. All commercial media we used can expand MSC but culturing cell in α-MEM. We used passage 4 of MSC to compare the media results, statistical analysis was performed using ANOVA and T-test. We successfully collected, isolation and culture equine BMMSC from horse sternum and ileum. After peroll centrifugation, higher number of Mononuclear cells (MNC) were obtained from RBC non-lysis technique rather than RBC lysis. Our MSC express most MSC specific markers (based on human). All media can support expression most MSC specific markers, but the dynamic of gene expression vary from each media and each MSC line. α-MEM support cell grew faster than other media. This MSC will be used to further studies and therapeutic purpose.
    Full-text · Technical Report · Feb 2015
  • Source
    • "The stromal compartment of bone marrow was the first source reported to contain MSCs (Fortier et al., 1998; Pittenger et al., 1999). For this reason, MSCs applied in tissue regeneration are still mainly isolated from this source and then amplified in vitro, following separation via plastic adherence (Bourzac et al., 2010). Furthermore, in regenerative medicine MSCs are frequently inoculated in association with Platelet Rich Plasma (PRP), a platelet concentrate able to improve tissue physiologic healing and return to function through the release of specific growth factors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of Mesenchymal Stromal Cells (MSCs) in orthopedic practice has recently and rapidly acquired an important role. Therapies based on the use of MSCs for the treatment of acute injuries as well as chronic inflammatory disorders are gradually becoming clinical routine. These cells have demonstrated intriguing therapeutic potentialities (i.e.: inflammation control, tissue regeneration and pathological scar prevention), that have been taken into consideration for use in both human and veterinary medicine. In particular, horses represent high performance athletes considered models for human pathologies since musculo-skeletal disorders frequently occur in this species. In the past, repair of tendon injures were performed by different methods. In particular, clinical therapy was based on ice application, bandage, box rest and controlled exercise. An alternative approach consisted on the use of corticosteroid (inflammation reduction) and other drugs (sodium hyaluronate, polysulphated glycosaminoglycans, beta aminoproprionitrile fumarate). Furthermore, surgical treatments like accessory ligament desmotomy, local irritation by line firing or pin firing were commonly used. More recently ultrasound, laser therapy, electromagnetic field therapy have been considered. Unfortunately, they did not allow complete tissue healing and quite often animals did not regain competitiveness. In order to minimize this inconvenience, the use of MSCs has been introduced as an alternative to the traditional approach since it represents a potential tool to improve tissue regeneration. Aim of this study was to evaluate the capability of MSCs to improve the functional outcome of horses affected by tendonitis and desmitis. Thirty-three breed and activity-matched horses affected by tendonitis or desmitis, were included in clinical trial scored for lesions and subdivided into two groups. Group 1 animals were treated with autologous MSCs, associated with platelet rich plasma (group 1). Bone marrow samples were collected from the sternum of the treated horses and processed in order to isolate MSCs. Following cell therapy, they were subjected to a rehabilitation period and their ability to resume training was evaluated. In this study, implanted MSCs caused no adverse reactions and thirteen out of the eighteen inoculated horses returned to race competitions. On the contrary, no improvement was seen in the twelve animals of group 2 treated with pin firing, that were not able to resume sport activity. In conclusion the clinical trial proves the safety of equine bone-marrow derived MSCs and a successful outcome of the treated animals that returned to their previous level of sport activity.
    Full-text · Article · Feb 2013 · Research in Veterinary Science
  • Source
    • "However arginase I was not detected in equine neutrophils isolated from peripheral blood using identical procedures, suggesting that equine and human neutrophils differ regarding their arginase isoform expression pattern. Arginase I mRNA was also undetected in both the mononuclear and polymorphonuclear cellular fractions isolated from equine bone marrow aspirates (not shown, n = 2) (Bourzac et al., 2010) as well as in neutrophil-rich BALF cells isolated from heaves-affected horses (n = 4, not shown). Arginase II mRNA was however detected in these cells suggesting that arginase I is not expressed by either myeloid or lymphoid cells in horses while arginase II is constitutively expressed in both cell lineages from early developmental stages. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neutrophils are the predominant cells recruited in the airways of horses suffering from heaves. These cells have been shown to express arginase in some species. The metabolism of L-arginine is thought to be involved in chronic inflammation, and airway obstruction and remodeling. The aim of this study was to assess the expression, regulation, activity, and functional role of arginase isoforms in equine neutrophils. Arginase I, arginase II, ornithine decarboxylase (ODC) and ornithine aminotransferase (OAT) expression were assessed in resting and stimulated (IL-4, LPS/fMLP, PMA; 5 and 18 h) blood neutrophils using quantitative PCR. Arginase expression was also studied by western blot and enzyme activity assay. The effect of nor-NOHA (1 mM), a specific arginase inhibitor, was assessed on arginase activity in vitro and ex vivo on neutrophil's inflammatory gene expression and viability. Results showed that equine neutrophils constitutively express arginase isoform 2,ODC and OAT. Neutrophil ex vivo stimulation did not induce arginase I nor influence arginase II mRNA expression. Ex vivo inhibition of arginase activity by nor-NOHA had no effect on neutrophils inflammatory gene expression induced by LPS/fMLP (5 h) but significantly reversed the cell loss observed after this stimulation.
    Full-text · Article · Jan 2013 · Veterinary Immunology and Immunopathology
Show more